Eric Peterson

Dec 4, 2024 | jamanetwork.com | Henry Chen |Eric Peterson |Ann Marie Navar |Benjamin Chong

Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus Key PointsQuestion  What is the incidence and prevalence of atherosclerotic cardiovascular disease (ASCVD) in persons with cutaneous lupus erythematosus (CLE) compared to the general population as well as persons with systemic lupus erythematosus and psoriasis?

Nov 17, 2024 | jamanetwork.com | Gregg C. Fonarow |Eric Peterson |Adrian Hernandez |Adrián Hernández

The Fine Art and Science of Translating Trials Results Into Clinical Practice Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure Orly Vardeny, PharmD, MS; Muthiah Vaduganathan, MD, MPH; Brian L. Claggett, PhD; Akshay S. Desai, MD, MPH; Pardeep S. Jhund, MBChB, MSc, PhD; Carolyn S. P. Lam, MBBS, PhD; Michele Senni, MD; Sanjiv J. Shah, MD; Adriaan A.

Mar 7, 2024 | journals.lww.com | Eric Peterson

Article In BriefGene therapies have transformed the treatment landscape for patients with neurologic conditions, especially rare pediatric neuromuscular disorders. But much is unknown about their possible outcomes, and concerns have arisen about cost of and access to these novel therapies. Here, researchers and clinicians discuss some of the ethical quandaries around making these gene therapies available to patients and their families.